ROCKVILLE, Md.--(BUSINESS WIRE)--
BIOQUAL, Inc. (OTC-Pink:BIOQ) ():
Nine Months Ended |
|
Three Months Ended |
||||||||||
|
February 28, |
|
February 29, |
|
February 28, |
|
February 29, |
|||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Revenue |
$ |
41,070,486 |
$ |
32,884,055 |
$ |
12,584,303 |
$ |
11,593,217 |
||||
Income Before Income Tax |
$ |
5,942,062 |
$ |
4,150,830 |
$ |
1,379,460 |
$ |
1,018,306 |
||||
Net Income |
$ |
4,203,962 |
$ |
2,936,730 |
$ |
975,960 |
$ |
720,406 |
||||
Basic Earnings per Share |
|
|
|
|
|
|
|
|
||||
of Common Stock |
$ |
4.70 |
$ |
3.29 |
$ |
1.09 |
$ |
.81 |
||||
Diluted Earnings per Share |
|
|
|
|
|
|
|
|
||||
of Common Stock |
$ |
4.70 |
$ |
3.29 |
$ |
1.09 |
$ |
.81 |
||||
Weighted Average |
|
|
|
|
|
|
|
|
||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
|
||||
For Basic Earnings Per Share |
|
893,932 |
|
893,416 |
|
894,416 |
|
893,416 |
||||
Weighted Average |
|
|
|
|
|
|
|
|
||||
Number of Shares Outstanding |
|
|
|
|
|
|
|
|
||||
For Diluted Earnings Per Share |
|
893,932 |
|
893,843 |
|
894,416 |
|
893,843 |
||||
For more detail related to the fiscal year 2021 unaudited third quarter results, please visit our web site at .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com:
